CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0651 (clinicaltrials.gov NCT No: NCT01110876)
Title:Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults with Recurrent Glioblastoma Multiforme
Principal Investigator:John DeGroot
Treatment Agent:Erlotinib; Temozolomide; Vorinostat
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the combination vorinostat and erlotinib, with or without temozolomide,
that can be given to patients with malignant gliomas. The safety of these drug
combinations will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:Erlotinib
Temozolomide
Vorinostat
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Merck and Co., Inc
Return Visit:every 4 weeks
Home Care:Patients will take vorinostst, temozolomide and erlotinib at home


Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults